WALTHAM, Mass. — Revvity, Inc. (NYSE: RVTY) announced the launch of Signals BioDesign, a cloud-native molecular cloning solution designed to simplify biologics research workflows for biotech and pharmaceutical R&D teams.
The new platform enables high-throughput construct design of up to 1,000 constructs while supporting real-time collaboration and data sharing across teams. It integrates directly with Revvity’s Signals One platform, connecting design processes with execution through a unified, cloud-based ecosystem.
Signals BioDesign brings together multiple molecular cloning techniques—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation within a single application. The company said the platform is designed to replace fragmented desktop tools and complex legacy systems with a streamlined, enterprise-grade solution.
According to Revvity, the system allows researchers to accelerate construct design, improve collaboration, and reduce data silos by operating within a centralized digital environment. Its integration with Signals One also links molecular design workflows to bioregistration and multi-modal experiment capture.
“The Signals BioDesign offering addresses a critical need for molecular biology teams developing the next generation of antibody, cell, and gene therapies,” said Kevin Willoe, president of Revvity Signals Software. “This solution empowers researchers with enterprise-ready collaboration and centralized construct management without the complexity of over-engineered platforms. By integrating directly with our Signals One platform, we’re focusing on enabling teams to accelerate therapeutic development timelines and bring life-saving treatments to patients faster.”
Revvity said the platform’s cloud-native architecture supports real-time collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls. Its multi-tenant SaaS model also reduces administrative overhead and compliance risks compared to traditional desktop software.
The company added that the system’s AI-ready data infrastructure positions research teams to adopt machine learning tools for sequence optimization and predictive design in the future.
Revvity plans to showcase Signals BioDesign at the Bio-IT World Conference & Expo, scheduled for May 19–21 in Boston, Massachusetts.
